ProMIS Neurosciences Inc. (PMN)
$13.47-$0.21 (-1.47%) Today
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
https://www.promisneurosciences.comSEC filings for PMN on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 1 | 2,280 | $30K |
44 Form 4 filings on record, the earliest from Oct 7, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Michael S. Gordon | Other | Tranche A Common Share Purchase Warrants | 119,800 | $0.00 | - | |
| Michael S. Gordon | Other | Tranche B Common Share Purchase Warrants | 119,800 | $0.00 | - | |
| Michael S. Gordon | Other | Tranche C Common Share Purchase Warrants | 119,800 | $0.00 | - | |
| Michael S. Gordon - 10% Owner | Open-market sale | Common Shares, no par value | 93,223 | - | - | |
| William W. Wyman - Director | Grant or award | Option (right to buy) | 20,000 | $0.00 | - | |
| Michael S. Gordon | Other | Common Shares, no par value | 48,333 | - | - | |
| Neil Cashman - Officer | Grant or award | Option (right to buy) | 200,000 | $0.00 | - | |
 Larry Douglas Altstiel - Officer | Grant or award | Option (right to buy) | 175,000 | $0.00 | - | |
| Max A. Milbury - Officer | Grant or award | Option (right to buy) | 70,000 | $0.00 | - | |
| Johanne Kaplan - Officer | Grant or award | Option (right to buy) | 175,000 | $0.00 | - | |
| Neil K. Warma - Officer | Grant or award | Option (right to buy) | 1,144,122 | $0.00 | - | |
| Neil K. Warma - Officer | Grant or award | Option (right to buy) | 490,338 | $0.00 | - | |
| Madge K. Shafmaster - Director | Grant or award | Option (right to buy) | 40,000 | $0.00 | - | |
| Patrick D. Kirwin - Director | Grant or award | Option (right to buy) | 40,000 | $0.00 | - | |
| Eugene Williams - Director | Grant or award | Option (right to buy) | 40,000 | $0.00 | - | |
| Josh Mandel-Brehm - Director | Grant or award | Option (right to buy) | 40,000 | $0.00 | - | |
| William W. Wyman - Director | Grant or award | Option (right to buy) | 40,000 | $0.00 | - |
This is as far as the anonymous view goes. Create a free account for all 44 PMN filings on record.
ProMIS Neurosciences Inc. (PMN) had 1 insider filing in the last 90 days, with the most recent on 2026-08-07. The full record for PMN runs to 44 Form 4 filings, the earliest from 2024-10-07. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
1 insider purchase of PMN was filed in the last 90 days, totaling $30K.
No insider sales of PMN were filed in the last 90 days. 1 sale is on record for this company.
This page tracks PMN Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add PMN to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
